Baseline | One year | Two years | ||||||
---|---|---|---|---|---|---|---|---|
Low-Tau1 AD patients n = 17 | High-Tau1 AD patients n = 10 | Low-Tau1 AD patients n = 17 | High-Tau1 AD patients n = 10 | Low-Tau1 AD patients n = 17 | High-Tau1 AD patients n = 10 | |||
Demographic data | Age (years) | 72.2 (4.2)* | 62.3 (5.3) | - | - | - | - | |
Sex (F/M) | 8/9 | 6/4 | - | - | - | - | ||
Education (years) | 14.4 (4.5) | 14.8 (4.4) | - | - | - | - | ||
Disease duration (years) | 5.4 (4.2) | 2.6 (1.0) | - | - | - | - | ||
Functional status | CDR | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
0.5 | 16 | 7 | 7 | 3 | 4 | 0 | ||
1 | 1 | 3 | 10 | 7 | 10 | 6 | ||
2 | 0 | 0 | 0 | 0 | 3 | 4 | ||
CDR sum of boxes | 3.4 (1.6) | 3.8 (2.1) | 4.7 (2.2) | 5.5 (1.5) | 6.5 (2.9) | 7.4 (2.5) | ||
Neuropsychological assessment | ||||||||
Global cognitive efficiency | MMSE (/30) | 24.8 (3.1) | 21.5 (2.2) | 23.6 (3.2) | 18.2 (2.3) | 21.4 (4.9)# | 13.9 (3.4) | |
Memory score | FCSRT (free + total immediate and delayed recalls) (/128) | 47.6 (25.7) | 78.1 (18.5) | 38.9 (29.3) | 52 (30.5) | 26 (28.2)# | 31.9 (28.5) | |
Instrumental score | (Naming + praxis + Rey figure copy) (/188) | 180.2 (4.1)* | 152.2 (23.2) | 177.5 (9.0) | 130.7 (28.2) | 167.3 (20.4)# | 104.7 (26.6) | |
Executive score | (Digit spans + letter fluency 2 min + WAIS similarities) | 46.4 (13.2) | 38.3 (10.1) | 48.9 (14.0) | 30.4 (9.7) | 46.3 (18.1)# | 23.7 (8.3) | |
Genetic status | ApoE genotype (n with at least one E4 allele) | 16 | 4 | - | - | - | - | |
CSF biomarkers | Amyloid peptide (pg/mL) | 482.5 (116.4) | 452.8 (112.4) | - | - | - | - | |
Total Tau (pg/mL) | 533.8 (176.7) | 821.9 (574.9) | - | - | - | - | ||
Phospho-tau181 (pg/mL) | 80 (27.3) | 99.3 (48.8) | - | - | - | - | ||
Molecular PET imaging | PiB-PET SUVr (GCI) | 2.84 (0.64) | 2.97 (0.76) | |||||
Mean Tau-PET SUVr (infero-medial temporal meta-VOI) | 1.42 (0.19) | 1.81 (0.43) | 1.57 (0.20)# | 1.75 (0.30) | ||||
Mean Tau-PET SUVr (lateral temporal VOI) | 1.32 (0.17) | 1.77 (0.34) | 1.44 (0.19)# | 1.67 (0.23) | ||||
Mean Tau-PET SUVr (lateral parietal VOI) | 1.18 (0.21)* | 2.1 (0.23) | 1.31 (0.27)# | 1.9 (0.19) | ||||
Mean Tau-PET SUVr (medial parietal VOI) | 1.21 (0.33) | 2.1 (0.40) | 1.34 (0.38) | 1.97 (0.28) | ||||
Mean Tau-PET SUVr (frontal VOI) | 1.06 (0.12) | 1.37 (0.23) | 1.12 (0.17) | 1.47 (0.23) | ||||
MRI | Fazekas score (0/1/2/3) | 8/6/2/1 | 6/3/1/0 | |||||
Mean normalized HV | 1.97 (0.28) | 2.14 (0.23) | 1.85 (0.28) | 1.97 (0.24) | ||||
Mean infero-medial temporal VOI CT (mm) | 2.57 (0.19) | 2.5 (0.16) | 2.45 (0.20) | 2.26 (0.16) | ||||
Mean lateral temporal VOI CT (mm) | 2.52 (0.13) | 2.47 (0.15) | 2.41 (0.17) | 2.24 (0.15) | ||||
Mean lateral parietal VOI CT (mm) | 2.15 (0.17)* | 1.89 (0.14) | 2.08 (0.17) | 1.74 (0.12) | ||||
Mean medial parietal VOI CT (mm) | 2.14 (0.17) | 1.93 (0.13) | 2.11 (0.15)# | 1.77 (0.12) | ||||
Mean frontal VOI CT (mm) | 2.39 (0.14) | 2.47 (0.09) | 2.36 (0.16) | 2.35 (0.11) |